Biomarkers of Acute Stroke Etiology (BASE) Study Methodology

Edward C. Jauch, Andrew D. Barreto, Joseph P. Broderick, Doug M. Char, Brett L. Cucchiara, Thomas G. Devlin, Alison J. Haddock, William J. Hicks, Brian C. Hiestand, Glen C. Jickling, Jeff June, David S. Liebeskind, Ted J. Lowenkopf, Joseph B. Miller, John O’Neill, Tim L. Schoonover, Frank R. Sharp, W. Frank Peacock

Acute ischemic stroke affects over 800,000 US adults annually, with hundreds of thousands more experiencing a transient ischemic attack. Emergent evaluation, prompt acute treatment, and identification of stroke or TIA (transient ischemic attack) etiology for specific secondary prevention are critical for decreasing further morbidity and mortality of cerebrovascular disease. The Biomarkers of Acute Stroke Etiology (BASE) study is a multicenter observational study to identify serum markers defining the etiology of acute ischemic stroke. Observational trial of patients presenting to the hospital within 24 h of stroke onset. Blood samples are collected at arrival, 24, and 48 h later, and RNA gene expression is utilized to identify stroke etiology marker candidates. The BASE study began January 2014. At the time of writing, there are 22 recruiting sites. Enrollment is ongoing, expected to hit 1000 patients by March 2017. The BASE study could potentially aid in focusing the initial diagnostic evaluation to determine stroke etiology, with more rapidly initiated targeted evaluations and secondary prevention strategies.Clinical Trial Registration Clinicaltrials.gov NCT02014896 https://clinicaltrials.gov/ct2/show/NCT02014896?term=biomarkers+of+acute+stroke+etiology&rank=1.